Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EM
Over three million people live with kidney disease in the UK. Some will progress to end-stage kidney disease, which is ultimately fatal, without either dialysis or kidney transplant.
Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by
Manufacturing problems wreaked havoc with Mallinckrodt's first attempt to secure FDA approval of its treatment candidate terlipressin for hepatorenal syndrome (HRS), but the drugmaker is ha
Manufacturing problems seem to have scuppered Mallinckrodt's hopes of bringing the first approved drug to market in the US for hepatorenal syndrome (HRS), a life-threatening condition that
In a new episode of the pharmaphorum podcast, Rahul Kakkar, CEO of gene editing company Tome, speaks with web editor Nicole Raleigh about programmable genomic integration (PGI) technology.<
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.